{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034446","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.388050+00:00","generated_at":"2026-05-16T21:01:14.248069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Talphera Q3 net loss $4.4M; cash $21.3M; Niyad study on track for H1 2026","bullets":["Net loss $4.4M ($0.11/sh) vs $3.4M ($0.13/sh) in Q3 2024.","Cash and investments $21.3M at Sept 30; sufficient through potential Niyad PMA approval late 2026.","Closed $17M first tranche financing led by CorMedix (CRMD); second tranche up to $29M conditional.","Five of nine NEPHRO trial sites activated; enrollment completion expected H1 2026.","Reduced 2025 cash operating expense guidance to $14-15M from $16-17M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034446","json":"https://secwatch.observer/filing/0001437749-25-034446.json","markdown":"https://secwatch.observer/filing/0001437749-25-034446.md","text":"https://secwatch.observer/filing/0001437749-25-034446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/0001437749-25-034446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/acrx20251108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:01:14.248069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}